Profound mishandling of protein glycation degradation products in uremia and dialysis.

The aim of this study was to define the severe deficits of protein glycation adduct clearance in chronic renal failure and elimination in peritoneal dialysis (PD) and hemodialysis (HD) therapy using a liquid chromatography-triple quadrupole mass spectrometric detection method. Physiologic proteolysis of proteins damaged by glycation, oxidation, and nitration forms protein glycation, oxidation, and nitration free adducts that are released into plasma for urinary excretion. Inefficient elimination of these free adducts in uremia may lead to their accumulation. Patients with mild uremic chronic renal failure had plasma glycation free adduct concentrations increased up to five-fold associated with a decline in renal clearance. In patients with ESRD, plasma glycation free adducts were increased up to 18-fold on PD and up to 40-fold on HD. Glycation free adduct concentrations in peritoneal dialysate increased over 2- to 12-h dwell time, exceeding the plasma levels markedly. Plasma glycation free adducts equilibrated rapidly with dialysate of HD patients, with both plasma and dialysate concentrations decreasing during a 4-h dialysis session. It is concluded that there are severe deficits of protein glycation free adduct clearance in chronic renal failure and in ESRD on PD and HD therapy.

[1]  T. Stompór,et al.  Selected Growth Factors in Peritoneal Dialysis: Their Relationship to Markers of Inflammation, Dialysis Adequacy, Residual Renal Function, and Peritoneal Membrane Transport , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[2]  G. Kaysen.  Albumin Turnover in Renal Disease , 1997, Mineral and Electrolyte Metabolism.

[3]  L. Sobrevia,et al.  Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. , 2003, Physiological reviews.

[4]  B. Matthews,et al.  Peptide methionine sulfoxide reductase: structure, mechanism of action, and biological function. , 2002, Archives of biochemistry and biophysics.

[5]  J. Baynes,et al.  Chemical modification of proteins by methylglyoxal. , 1998, Cellular and molecular biology.

[6]  T. Niwa,et al.  Localization of imidazolone in the peritoneum of capd patients: a factor for a loss of ultrafiltration. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  C. Visser,et al.  Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients. , 1996, Journal of the American Society of Nephrology : JASN.

[8]  H. Erbersdobler,et al.  Metabolic Transit and in vivo Effects of Melanoidins and Precursor Compounds Deriving from the Maillard Reaction , 2001, Annals of Nutrition and Metabolism.

[9]  T. Lyons,et al.  Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. , 1997, The Journal of clinical investigation.

[10]  A. Torres,et al.  Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Anne Dawnay,et al.  Estimation of α-oxoaldehydes formed from the degradation of glycolytic intermediates and glucose fragmentation in blood plasma of human subjects with uraemia , 2002 .

[12]  Paul J Thornalley,et al.  Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin. , 2002, The Biochemical journal.

[13]  Paul J Thornalley.  THE CLINICAL SIGNIFICANCE OF GLYCATION , 1999 .

[14]  E G Lowrie,et al.  The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. , 1993, The New England journal of medicine.

[15]  P. Finot,et al.  Identification of N.epsilon.-carboxymethyllysine: a new Maillard reaction product in rat urine , 1987 .

[16]  J. Lundahl,et al.  Three monocyte-related determinants of atherosclerosis in haemodialysis. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  J. Heinecke,et al.  Artifact-free quantification of free 3-chlorotyrosine, 3-bromotyrosine, and 3-nitrotyrosine in human plasma by electron capture-negative chemical ionization gas chromatography mass spectrometry and liquid chromatography-electrospray ionization tandem mass spectrometry. , 2002, Analytical biochemistry.

[18]  K. Nitta,et al.  Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  B. Lindholm,et al.  Pathophysiology of Peritoneal Membrane Failure , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[20]  T. Henle.  AGEs in foods: do they play a role in uremia? , 2003, Kidney international. Supplement.

[21]  K. Maeda,et al.  Increase in three alpha,beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. , 1999, Biochemical and biophysical research communications.

[22]  T. Henle,et al.  Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids. , 2001, Contributions to Nephrology.

[23]  D. Predescu,et al.  Transport of nitrated albumin across continuous vascular endothelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Rocco,et al.  Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. , 2000, Kidney international.

[25]  Paul J Thornalley,et al.  Methylglyoxal-modified arginine residues--a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. , 1997, Biochimica et biophysica acta.

[26]  Anne Dawnay,et al.  Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. , 2003, The Biochemical journal.

[27]  P. Lim,et al.  8-Iso-Prostaglandin F2α as a Useful Clinical Biomarker of Oxidative Stress in ESRD Patients , 2003, Blood Purification.

[28]  C. Schalkwijk,et al.  Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. , 2004, Kidney international.

[29]  K. Maeda,et al.  Increase in Three α,β-Dicarbonyl Compound Levels in Human Uremic Plasma: Specificin VivoDetermination of Intermediates in Advanced Maillard Reaction , 1999 .

[30]  T. Imaizumi,et al.  Role of Lipoprotein (a) and TGF-β1 in Atherosclerosis of Hemodialysis Patients , 2000 .

[31]  V. Monnier,et al.  Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. , 1996, The Journal of clinical investigation.

[32]  Raymond Vanholder,et al.  Review on uremic toxins: classification, concentration, and interindividual variability. , 2003, Kidney international.

[33]  C. Ronco,et al.  The peritoneal dialysis system. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  Paul J Thornalley,et al.  Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, N epsilon-(1-deoxy-D-fructos-1-yl)hippuryl-lysine. , 1992, European journal of biochemistry.

[35]  J. Lundahl,et al.  Monocyte-Related Determinants of Inflammation in Patients on Peritoneal Dialysis , 2001, American Journal of Nephrology.

[36]  M. Portero-Otín,et al.  Chemical and Immunological Characterization of Oxidative Nonenzymatic Protein Modifications in Dialysis Fluids , 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[37]  H. Kusuhara,et al.  Characterization of uremic toxin transport by organic anion transporters in the kidney. , 2004, Kidney international.